Biogen将收购Apellis pharmaceuticals for $56 billion

Biogen has agreed to buy Apellis pharmaceuticals for $56 billion, expanding its capabilities in the immune system and rare diseases. This is the company's largest deal in its history. The company will pay $41 per share, which is more than double the closing price of Apellis on Monday. Apellis' stock has dropped by 32% so far this year.通过 this deal, Biogen will gain two approved drugs. Apellis' most popular drug is Syfoire, used to treat an immune system disease that causes blindness, with annual sales of $5.87 billion. Another product is Empaveli, used to treat blood diseases and rare肾diseases, with annual sales exceeding $1 billion. Editor:刘明亮.ents:新浪财经 statement: This message is published from a合作 medium. The newspaper登载此文为了传递更多信息，文章内容仅作为参考，不构成投资建议.郑重 statement: 1. According to the《securities法》, it is prohibited to contrive, spread false information or misleading information to disrupt the stock market; 2. users in this community may post all data, comments, etc., which represent their own points of view, and are not necessarily consistent with the website's position.用户 should base their investment decisions on their own independent judgment and assume corresponding risks.